vs
ANI PHARMACEUTICALS INC（ANIP）とONESPAWORLD HOLDINGS Ltd（OSW）の財務データ比較。上の社名をクリックして会社を切り替えられます
ANI PHARMACEUTICALS INCの直近四半期売上が大きい（$247.1M vs $242.1M、ONESPAWORLD HOLDINGS Ltdの約1.0倍）。ANI PHARMACEUTICALS INCの純利益率が高く（11.1% vs 5.0%、差は6.1%）。ANI PHARMACEUTICALS INCの前年同期比売上増加率が高い（29.6% vs 11.5%）。ANI PHARMACEUTICALS INCの直近四半期フリーキャッシュフローが多い（$29.1M vs $14.9M）。過去8四半期でANI PHARMACEUTICALS INCの売上複合成長率が高い（34.1% vs 7.1%）
ANIファーマシューティカルズは米国に本社を置く特殊製薬会社で、後発医薬品とブランド処方薬の研究開発・製造・販売を行っています。主力製品分野は皮膚科、腫瘍、中枢神経系治療、感染症対策で、主に米国内の医療機関、調剤薬局、患者を対象としています。
ANIP vs OSW — 直接比較
売上が大きい
ANIP
1.0倍大きい
$242.1M
売上成長率が高い
ANIP
+18.2%の差
11.5%
純利益率が高い
ANIP
純利益率が6.1%高い
5.0%
フリーキャッシュフローが多い
ANIP
FCF $14.2M多い
$14.9M
2年売上CAGRが高い
ANIP
2年複合成長率
7.1%
損益計算書 — Q4 FY2025 vs Q4 FY2025
| 指標 | | |
|---|---|---|
| 売上 | $247.1M | $242.1M |
| 純利益 | $27.5M | $12.1M |
| 粗利率 | — | — |
| 営業利益率 | 14.1% | 6.8% |
| 純利益率 | 11.1% | 5.0% |
| 売上前年比 | 29.6% | 11.5% |
| 純利益前年比 | 367.5% | -16.2% |
| EPS（希薄化後） | $1.14 | $0.12 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
売上ANIPOSW
| Q4 25 | $247.1M | $242.1M | ||
| Q3 25 | $227.8M | $258.5M | ||
| Q2 25 | $211.4M | $240.7M | ||
| Q1 25 | $197.1M | $219.6M | ||
| Q4 24 | $190.6M | $217.2M | ||
| Q3 24 | $148.3M | $241.7M | ||
| Q2 24 | $138.0M | $224.9M | ||
| Q1 24 | $137.4M | $211.2M |
純利益ANIPOSW
| Q4 25 | $27.5M | $12.1M | ||
| Q3 25 | $26.6M | $24.3M | ||
| Q2 25 | $8.5M | $19.9M | ||
| Q1 25 | $15.7M | $15.3M | ||
| Q4 24 | $-10.3M | $14.4M | ||
| Q3 24 | $-24.2M | $21.6M | ||
| Q2 24 | $-2.3M | $15.8M | ||
| Q1 24 | $18.2M | $21.2M |
営業利益率ANIPOSW
| Q4 25 | 14.1% | 6.8% | ||
| Q3 25 | 15.9% | 10.2% | ||
| Q2 25 | 6.6% | 9.2% | ||
| Q1 25 | 13.3% | 7.7% | ||
| Q4 24 | -2.3% | 7.9% | ||
| Q3 24 | -13.8% | 10.3% | ||
| Q2 24 | 3.7% | 8.4% | ||
| Q1 24 | 14.8% | 8.0% |
純利益率ANIPOSW
| Q4 25 | 11.1% | 5.0% | ||
| Q3 25 | 11.7% | 9.4% | ||
| Q2 25 | 4.0% | 8.3% | ||
| Q1 25 | 8.0% | 7.0% | ||
| Q4 24 | -5.4% | 6.6% | ||
| Q3 24 | -16.3% | 8.9% | ||
| Q2 24 | -1.7% | 7.0% | ||
| Q1 24 | 13.2% | 10.0% |
EPS（希薄化後）ANIPOSW
| Q4 25 | $1.14 | $0.12 | ||
| Q3 25 | $1.13 | $0.23 | ||
| Q2 25 | $0.36 | $0.19 | ||
| Q1 25 | $0.69 | $0.15 | ||
| Q4 24 | $-0.45 | $0.13 | ||
| Q3 24 | $-1.27 | $0.20 | ||
| Q2 24 | $-0.14 | $0.15 | ||
| Q1 24 | $0.82 | $0.21 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $285.6M | $16.3M |
| 総負債低いほど良い | — | $84.0M |
| 株主資本純資産 | $540.7M | $542.6M |
| 総資産 | $1.4B | $707.1M |
| 負債/資本比率低いほどレバレッジが低い | — | 0.15× |
8四半期トレンド — 暦四半期で整列
現金・短期投資ANIPOSW
| Q4 25 | $285.6M | $16.3M | ||
| Q3 25 | $262.6M | $29.6M | ||
| Q2 25 | $217.8M | $35.0M | ||
| Q1 25 | $149.8M | $22.6M | ||
| Q4 24 | $144.9M | $57.4M | ||
| Q3 24 | $145.0M | $48.8M | ||
| Q2 24 | $240.1M | $62.5M | ||
| Q1 24 | $228.6M | $65.4M |
総負債ANIPOSW
| Q4 25 | — | $84.0M | ||
| Q3 25 | — | $85.2M | ||
| Q2 25 | — | $96.2M | ||
| Q1 25 | — | $97.4M | ||
| Q4 24 | — | $98.6M | ||
| Q3 24 | — | $98.7M | ||
| Q2 24 | — | $123.8M | ||
| Q1 24 | — | $138.6M |
株主資本ANIPOSW
| Q4 25 | $540.7M | $542.6M | ||
| Q3 25 | $505.8M | $552.8M | ||
| Q2 25 | $436.8M | $548.3M | ||
| Q1 25 | $418.6M | $530.6M | ||
| Q4 24 | $403.7M | $554.5M | ||
| Q3 24 | $405.9M | $540.1M | ||
| Q2 24 | $455.8M | $532.7M | ||
| Q1 24 | $452.0M | $515.5M |
総資産ANIPOSW
| Q4 25 | $1.4B | $707.1M | ||
| Q3 25 | $1.4B | $732.6M | ||
| Q2 25 | $1.3B | $731.8M | ||
| Q1 25 | $1.3B | $708.7M | ||
| Q4 24 | $1.3B | $746.4M | ||
| Q3 24 | $1.3B | $734.0M | ||
| Q2 24 | $920.8M | $756.8M | ||
| Q1 24 | $914.5M | $763.6M |
負債/資本比率ANIPOSW
| Q4 25 | — | 0.15× | ||
| Q3 25 | — | 0.15× | ||
| Q2 25 | — | 0.18× | ||
| Q1 25 | — | 0.18× | ||
| Q4 24 | — | 0.18× | ||
| Q3 24 | — | 0.18× | ||
| Q2 24 | — | 0.23× | ||
| Q1 24 | — | 0.27× |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $30.4M | $20.0M |
| フリーキャッシュフロー営業CF - 設備投資 | $29.1M | $14.9M |
| FCFマージンFCF / 売上 | 11.8% | 6.2% |
| 設備投資強度設備投資 / 売上 | 0.5% | 2.1% |
| キャッシュ転換率営業CF / 純利益 | 1.10× | 1.65× |
| 直近12ヶ月FCF直近4四半期 | $171.4M | $68.4M |
8四半期トレンド — 暦四半期で整列
営業キャッシュフローANIPOSW
| Q4 25 | $30.4M | $20.0M | ||
| Q3 25 | $44.1M | $33.2M | ||
| Q2 25 | $75.8M | $20.3M | ||
| Q1 25 | $35.0M | $10.1M | ||
| Q4 24 | $15.9M | $16.6M | ||
| Q3 24 | $12.5M | $28.6M | ||
| Q2 24 | $17.4M | $18.7M | ||
| Q1 24 | $18.3M | $15.0M |
フリーキャッシュフローANIPOSW
| Q4 25 | $29.1M | $14.9M | ||
| Q3 25 | $38.0M | $27.6M | ||
| Q2 25 | $71.8M | $17.6M | ||
| Q1 25 | $32.5M | $8.4M | ||
| Q4 24 | $13.5M | $13.2M | ||
| Q3 24 | $7.7M | $27.5M | ||
| Q2 24 | $13.0M | $17.6M | ||
| Q1 24 | $13.7M | $13.7M |
FCFマージンANIPOSW
| Q4 25 | 11.8% | 6.2% | ||
| Q3 25 | 16.7% | 10.7% | ||
| Q2 25 | 34.0% | 7.3% | ||
| Q1 25 | 16.5% | 3.8% | ||
| Q4 24 | 7.1% | 6.1% | ||
| Q3 24 | 5.2% | 11.4% | ||
| Q2 24 | 9.4% | 7.8% | ||
| Q1 24 | 10.0% | 6.5% |
設備投資強度ANIPOSW
| Q4 25 | 0.5% | 2.1% | ||
| Q3 25 | 2.7% | 2.2% | ||
| Q2 25 | 1.9% | 1.1% | ||
| Q1 25 | 1.3% | 0.8% | ||
| Q4 24 | 1.3% | 1.5% | ||
| Q3 24 | 3.2% | 0.5% | ||
| Q2 24 | 3.2% | 0.5% | ||
| Q1 24 | 3.3% | 0.6% |
キャッシュ転換率ANIPOSW
| Q4 25 | 1.10× | 1.65× | ||
| Q3 25 | 1.66× | 1.36× | ||
| Q2 25 | 8.87× | 1.02× | ||
| Q1 25 | 2.23× | 0.66× | ||
| Q4 24 | — | 1.15× | ||
| Q3 24 | — | 1.33× | ||
| Q2 24 | — | 1.19× | ||
| Q1 24 | 1.00× | 0.71× |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
ANIP
| Sales Of Cortrophin Gel | $111.4M | 45% |
| Sales Of Generic Pharmaceutical Products | $100.8M | 41% |
| Sales Of ILUVIEN And YUTIQ | $19.8M | 8% |
| Sales Of Established Brands | $12.3M | 5% |
| Unapproved Products | $6.5M | 3% |
| Sales Of Royalties And Other Pharmaceutical Services | $2.7M | 1% |
OSW
| Services | $197.3M | 82% |
| Products | $44.8M | 18% |
